GregorySMontgomeryMD

Pediatric Pulmonology • Indianapolis, IN

Chronic Lung Disease of Prematurity and Infancy, Pediatric Bronchoscopy, Pediatric Interstitial Lung Disease Pulmonology

Professor of Clinical Pediatrics; Medical Director, Pediatric PH Center of Comprehensive Care; Director, Bronchoscopy Program; Director, Pulmonary Inpatient Services

Join to view full profile

Dr. Montgomery is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Montgomery's full profile

Already have an account?

Office
705 Riley Hospital Dr
Pulmonary MSA
Indianapolis, IN 46202
Phone+1 317-948-7208

Fax+1 317-944-5791

Summary

Dr. Gregory Montgomery is a pediatric pulmonologist in Indianapolis, IN and is affiliated with multiple hospitals in the area, including Riley Hospital for Children at Indiana University Health, Indiana University Health North Hospital, and Eskenazi Health. He received his medical degree from Indiana University School of Medicine and has been in practice 19 years. He specializes in pediatric pulmonary hypertension, chronic lung disease of prematurity and infancy, pediatric flexible bronchoscopy, pediatric interstitial and rare lung disease and pediatric exercise physiology.

Clinical Expertise

Pulmonary hypertension, Bronchopulmonary dysplasia, Pediatric bronchoscopy, Pediatric exercise physiology, General pulmonology, Pediatric interstitial lung disease

Education & Training

University of ColoradoFellowship, Pediatric Pulmonology, 2002 - 2005
University of MinnesotaChief Residency, Pediatrics, 2001 - 2002
University of MinnesotaResidency, Pediatrics, 1999 - 2001
University of MinnesotaInternship, Pediatrics, 1998 - 1999
Indiana University School of MedicineClass of 1998
Indiana UniversityBS, Biology, 1990 - 1994

Certifications & Licensure

IN State Medical License 2005 - 2025
CO State Medical License 2002 - 2005
MN State Medical License 2001 - 2003
American Board of Pediatrics Pediatric Pulmonology

Awards, Honors, & Recognition

Indianapolis Top Doctor Castle Connelly, 2016-2023

Clinical Trials

Antimicrobial Resistance in Cystic Fibrosis (CF) Start of enrollment: 2006 Mar 01
Completed
Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation Start of enrollment: 2007 Dec 01
Completed
MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis Start of enrollment: 2010 Nov 04
Completed
Phase 3
Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients Start of enrollment: 2011 Jan 01
Completed
Phase 3
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension Start of enrollment: 2012 Jul 17
Completed
Phase 1, Phase 2
G551D Observational Study- Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2) Start of enrollment: 2014 Jan 01
Completed
Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation Start of enrollment: 2013 Jan 01
Completed
Phase 3
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation Start of enrollment: 2013 Apr 01
Completed
Phase 3
An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis Start of enrollment: 2013 May 01
Completed
Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Start of enrollment: 2013 Jul 01
Completed
Phase 3
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis Start of enrollment: 2013 Oct 01
Completed
Phase 3
Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation Start of enrollment: 2013 Dec 01
Completed
Phase 3
A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT) Start of enrollment: 2015 Mar 01
Completed
A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation Start of enrollment: 2015 Aug 01
Completed
Phase 3
Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor Start of enrollment: 2015 Aug 01
Completed
Phase 3
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation Start of enrollment: 2016 Jun 02
Completed
Phase 3
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del Start of enrollment: 2016 May 01
Completed
Phase 3
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) Start of enrollment: 2017 Oct 24
Recruiting
Phase 3
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF) Start of enrollment: 2016 Nov 01
Completed
Phase 3
A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Start of enrollment: 2017 May 12
Completed
Phase 3
A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation Start of enrollment: 2017 Aug 16
Completed
Phase 3
A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD) Start of enrollment: 2019 Dec 03
Completed
Phase 3
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension Start of enrollment: 2020 Jan 16
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

5 citations
Propranolol in the treatment of upper airway hemangiomas.
Lauren C.Anderson de Moreno, Bruce H. Matt, Gregory S. Montgomery, Young Jee Kim
Ear, Nose, & Throat Journal. 2013-04-01
11 citations
The US national registry for childhood interstitial and diffuse lung disease: Report of study design and initial enrollment cohort.
Rebekah J Nevel, Gail H Deutsch, Daniel Craven, Robin Deterding, Martha P Fishman
Pediatric Pulmonology. 2024-09-01
176 citations
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
Margaret Rosenfeld, Claire E. Wainwright, Mark Higgins, Linda T Wang, Charlotte M. McKee
The Lancet. Respiratory Medicine. 2018-07-01

Books/Book Chapters

Pediatric Respiratory Medicine
Chapter: Thoracic tumors
Page 1025 - 1030Deterding RR, Montgomery GSEditors: Taussig L, Landau L.Mosby/Elsevier, Philadelphia, PAEdition 2nd,2008

Authored Content

Pediatric Pulmonologists Say Kids Should Mask UpAugust 2021

Press Mentions

She dreamed of building rockets. What's happened since Annie's death will help others soarApril 15th, 2024
“He’s a happy boy … when he’s not having a sickle cell flare-up”September 26th, 2023
Riley Pediatric Pulmonary Hypertension program receives PHA accreditation as PHCCJune 1st, 2023
Join now to see all

Committees

Physician Member, Pulmonary Hypertension Association PHPN Symposium Planning Committee 2020 - 2024
Data Monitoring Committee Member, CF Foundation Therapeutics Data & Safety Monitoring Board 2011 - 2022